தீர்மானம் உயிர் அறிவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தீர்மானம் உயிர் அறிவியல் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தீர்மானம் உயிர் அறிவியல் இன்க் Today - Breaking & Trending Today

Global Liquid Biopsy Market Review 2019-2020 and Forecast 2021-2025 with Profiles of Over 200 Competitors


Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarker ....

United States , Diamir Bio , Cegat Gmbh , Pacific Biosciences , Cambridge Epigenetix , Twinstrand Biosciences , Telexos Gmbh , Codiak Biosciences , Capio Biosciences , Circulogene Theranostics , Laura Wood , Koninklijke Philips , Sysmex Inostics Gmbh , Apostle Inc , Burning Rock Biotech Ltd , Quantapore Inc , Biofluidica Inc , Namocell Inc , Nrichdx Inc , Dnanexus Inc , Seracare Life Sciences Inc , Id Solutions , Yikon Genomics Co Ltd , Labrinth Biotech Inc , Exosome Sciences Inc , Quantgene Inc ,

Agilent to acquire Resolution Bioscience for $695 M


Agilent to acquire Resolution Bioscience for $695 M
Agilent to acquire Resolution Bioscience for $695 M
03 March 2021 | News
Source credit: Shutterstock
Agilent Technologies Inc has announced that it has entered into a definitive agreement to acquire Resolution Bioscience Inc, a leader in the development and commercialisation of next-generation sequencing (NGS)-based precision oncology solutions.
The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.
Under the terms of the agreement, Agilent will pay $550 million in cash at closing and up to an additional $145 million based on achieving future performance milestones. ....

United States , Mike Mcmullen , Mark Li , Agilent Technologies Inc , Resolution Bioscience Inc , Clinical Laboratory Improvement Amendments , Resolution Bioscience , Agilent Technologies , Ngs Based , Cancer Diagnostics , Biopharma Services , Clinical Oncology , Diagnostic Testing Market , Clia Certified Lab , ஒன்றுபட்டது மாநிலங்களில் , மைக் மகலெந் , குறி லி , தீர்மானம் உயிர் அறிவியல் இன்க் , மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் , தீர்மானம் உயிர் அறிவியல் , ஂக்ஸ் அடிப்படையிலானது , புற்றுநோய் பரிசோதனை , மருத்துவ புற்றுநோயியல் , கண்டறியும் சோதனை சந்தை , கிளியா சிஇஆர்டிஐஎஃப்ஐஇடி ஆய்வகம் ,

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population


3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.2 Single Cell Genomics Changes the Picture
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magnetoresistance based assay
4. Cancer Panels & Profiles Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
Metastatic Cancer Markers Identified in Clinical WGS Study
Stitch Bio Bets on CRISPR Tech
Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx ....

United States , Miltenyi Biotec , Yourgene Elucigene , Siemens Healthineers , Qiagen Gmbh , Sysmex Inostics , Laura Wood , Academic Research Lab , Testing Lab , Public National , Central Lab , Technology Development , Singlera Genomics Inc , Invitae Corporation , Physician Office Lab , Enzo Life Sciences Inc , Office Hours Call , Biodesix Inc , Datar Cancer Genetics , Fluidigm Corp , Accuragen Inc , Business Development Staff , Genefirst Ltd , Bioneer Corporation , Genomics Co , Thermo Fisher Scientific Inc ,

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Perkin Elmer , Miltenyi Biotec , Yourgene Elucigene , Siemens Healthineers , Qiagen Gmbh , Sysmex Inostics , Laura Wood , Academic Research Lab , Testing Lab , Public National , Central Lab , Technology Development , Singlera Genomics Inc , Invitae Corporation , Physician Office Lab , Enzo Life Sciences Inc , Office Hours Call , Biodesix Inc , Datar Cancer Genetics , Fluidigm Corp , Accuragen Inc , Business Development Staff , Genefirst Ltd , Bioneer Corporation , Genomics Co ,